Claire Mazumdar Named Successor at Biocon

By: WE Staff | Tuesday, 5 May 2026

• Claire Mazumdar named successor to lead Biocon
• Currently leads Bicara Therapeutics and took it public on NASDAQ
• MIT & Stanford-trained biotech leader set for gradual transition into Biocon leadership

Biocon founder Kiran Mazumdar-Shaw has reportedly named her niece Claire Mazumdar as her successor to lead Biocon.

The reported successor of Biocon, Claire Mazumdar is currently leading a biotech firm called Bicara Therapeutics that was incubated by Biocon. She has built experience in the pharmaceutical and biotechnology space and is seen as part of the company’s next generation of leadership.

The transition is not expected to happen immediately. Mazumdar-Shaw will continue to lead Biocon for now, while Claire gradually takes on a bigger role within the company. The company will be handed over smoothly without affecting business operations.

“I have seen my niece Claire as my successor, because I think she has proved to me that she can run a company,” she said.

Claire is the founding CEO of Bicara therapeutics; a US based company incubated via Biocon who develops new cancer treatments. Under her leadership the company went public on NASDAQ in 2024 with a market cap that has exceeded $1.6 billion (with the company still developing their lead therapy).

Academically, Claire holds an engineering degree from the Massachusetts Institute of Technology (MIT) in biological engineering, as well an MBA from Stanford Graduate School of Business, and a PhD from Stanford in cancer biology. Claire has published research regarding tumour immunology and cancer epigenetics in top journals, including Nature and Cell Stem Cell.

Apart from her academic achievements, Claire remains relatively low key in the public domain compared with her aunt who built Biocon into India’s largest biotech company and the worldwide leader in manufacturing biosimilars.

At a time of great change at Biocon, a company moving towards biosimilars, Mazumdar-Shaw has stated that Claire will be supported by an expansive ecosystem comprising her brother , as well as her husband along with other family and professional leaders.

While no official timeline for the transition has been provided, many industry insiders believe that Claire Mazumdar's role at Biocon will expand dramatically in the near future.

Until then, Claire remains somewhat of an enigma at Biocon; extremely well-qualified and world-trained, she continues to work primarily behind the scenes. As Biocon matures into its next phase of growth, Claire's low profile may change rapidly.